Aspen Pharmacare
Aspen Pharmacare, a leading global pharmaceutical company headquartered in South Africa (ZA), has established itself as a key player in the healthcare industry since its founding in 1850. With a strong presence in over 50 countries, Aspen operates primarily in the areas of generic and branded pharmaceuticals, as well as consumer healthcare products. The company is renowned for its diverse portfolio, which includes anaesthetics, thrombosis, and oncology medications, setting it apart through a commitment to quality and innovation. Aspen's strategic acquisitions and partnerships have bolstered its market position, making it one of the largest pharmaceutical manufacturers in Africa. Notable achievements include its rapid expansion into international markets and a focus on sustainable healthcare solutions, reinforcing its reputation as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Aspen Pharmacare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aspen Pharmacare's score of 62 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aspen Pharmacare's reported carbon emissions
In 2024, Aspen Pharmacare reported total carbon emissions of approximately 32468000 kg CO2e for Scope 1, 108515000 kg CO2e for Scope 2, and 200000000 kg CO2e for Scope 3 emissions. This represents a significant portion of their overall carbon footprint, with Scope 3 emissions primarily driven by purchased goods and services, accounting for about 150000000 kg CO2e. Aspen has set ambitious climate commitments, aiming to reduce global carbon dioxide emissions by 45% by 2030 relative to 2010 levels, with a long-term goal of achieving net zero emissions by around mid-century. Over the past five years, the company has realised a 28% reduction in combined Scope 1 and Scope 2 emissions, equating to approximately 57693 tonnes CO2e. In terms of specific reductions, Aspen has committed to reducing Scope 2 emissions by 30% from a 2020 baseline by 2030 and aims to bring Scope 1 emissions to near zero by the middle of this decade. These initiatives reflect Aspen's dedication to sustainability and its proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,609,000 | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,278,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aspen Pharmacare is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
